2022 · Clinica chimica acta; international journal of clinical chemistry · paywalled
Evaluation of volumetric blood collection devices for the measurement of phenylalanine and tyrosine to monitor patients with phenylketonuria
Carling et al.
The finding, in our words
Three volumetric dried blood devices (HemaXis-DB10, Capitainer-qDBS and Neoteryx-Mitra) were compared with conventional PerkinElmer DBS cards for phenylalanine and tyrosine measurement in phenylketonuria monitoring. Blood volume did not affect the volumetric devices but caused significant bias with conventional cards, and all volumetric devices agreed better with liquid blood, with HemaXis-DB10 showing the smallest bias at 5.1 per cent versus 32.6 per cent for conventional DBS. Higher haematocrit still introduced unacceptable bias for Neoteryx-Mitra and conventional DBS, suggesting volumetric devices improve decentralised biochemical monitoring of PKU patients but do not fully eliminate the
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
The study validated an LC-MS/MS method for eight antiepileptic drugs and two metabolites in dried blood spot and VAMS formats, with satisfactory analytical performance and stability, and was the first to include the oxcarbazepine metabolite DHCB. In 80 paired patient samples, microsampling concentrations showed promising correlation with plasma, supporting decentralised therapeutic drug monitoring of antiepileptic treatment.
Cobo-Golpe et al., Journal of analytical toxicology · source ↗
Untargeted metabolomic profiles from three blood microsampling devices aligned more closely with whole blood than with plasma, and all devices distinguished sex based on amino acids, lipids, and acylcarnitines. This validates that device choice can be tailored to the metabolites of interest for decentralised human biomonitoring.
Avella et al., Metabolomics : Official journal of the Metabolomic Society · source ↗
In matched clinical samples from rheumatoid arthritis, VAMS and DBS showed strong agreement for methotrexate polyglutamates (slopes 0.95-1.07; bias within -4.21% to 0.36%; SRCC ≥ 0.969), with up to 100% of total MTXPG results within ±20% limits; capillary microsampling agreed closely with whole blood but differed from red blood cells, indicating matrix-specific differences that must be accounted for when interpreting against RBC-based reference values.
Kocur et al., International journal of molecular sciences · source ↗